Sialoglycan recognition is a common connection linking acidosis, zinc, and HMGB1 in sepsis.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
09 03 2021
Historique:
entrez: 4 3 2021
pubmed: 5 3 2021
medline: 12 3 2021
Statut: ppublish

Résumé

Blood pH is tightly maintained between 7.35 and 7.45, and acidosis (pH <7.3) indicates poor prognosis in sepsis, wherein lactic acid from anoxic tissues overwhelms the buffering capacity of blood. Poor sepsis prognosis is also associated with low zinc levels and the release of High mobility group box 1 (HMGB1) from activated and/or necrotic cells. HMGB1 added to whole blood at physiological pH did not bind leukocyte receptors, but lowering pH with lactic acid to mimic sepsis conditions allowed binding, implying the presence of natural inhibitor(s) preventing binding at normal pH. Testing micromolar concentrations of divalent cations showed that zinc supported the robust binding of sialylated glycoproteins with HMGB1. Further characterizing HMGB1 as a sialic acid-binding lectin, we found that optimal binding takes place at normal blood pH and is markedly reduced when pH is adjusted with lactic acid to levels found in sepsis. Glycan array studies confirmed the binding of HMGB1 to sialylated glycan sequences typically found on plasma glycoproteins, with binding again being dependent on zinc and normal blood pH. Thus, HMGB1-mediated hyperactivation of innate immunity in sepsis requires acidosis, and micromolar zinc concentrations are protective. We suggest that the potent inflammatory effects of HMGB1 are kept in check via sequestration by plasma sialoglycoproteins at physiological pH and triggered when pH and zinc levels fall in late stages of sepsis. Current clinical trials independently studying zinc supplementation, HMGB1 inhibition, or pH normalization may be more successful if these approaches are combined and perhaps supplemented by infusions of heavily sialylated molecules.

Identifiants

pubmed: 33658363
pii: 2018090118
doi: 10.1073/pnas.2018090118
pmc: PMC7958265
pii:
doi:

Substances chimiques

Carrier Proteins 0
HMGB1 Protein 0
Lipopolysaccharides 0
Polysaccharides 0
Sialic Acids 0
Sialoglycoproteins 0
Zinc J41CSQ7QDS

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR070179
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM032373
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL094463
Pays : United States

Informations de copyright

Copyright © 2021 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Am J Physiol Gastrointest Liver Physiol. 2015 Nov 1;309(9):G768-78
pubmed: 26272258
J Mol Med (Berl). 2016 Feb;94(2):219-33
pubmed: 26411873
Gene. 2007 Jan 31;387(1-2):133-40
pubmed: 17156942
Glycobiology. 1999 Oct;9(10):1003-8
pubmed: 10521536
J Clin Invest. 2003 Sep;112(6):853-62
pubmed: 12975470
Expert Opin Ther Targets. 2014 Mar;18(3):257-68
pubmed: 24392842
J Exp Med. 2012 Aug 27;209(9):1519-28
pubmed: 22869893
Br J Anaesth. 2015 Jun;114(6):990-9
pubmed: 25833826
Annu Rev Immunol. 2010;28:367-88
pubmed: 20192808
Med Hypotheses. 2004;63(4):691-5
pubmed: 15325019
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Cytokine. 2010 Aug;51(2):119-26
pubmed: 20347329
Thorax. 2009 Sep;64(9):798-805
pubmed: 19497921
J Exp Med. 2000 Aug 21;192(4):565-70
pubmed: 10952726
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
J Biol Chem. 2014 Dec 19;289(51):35237-45
pubmed: 25391648
Science. 1999 Jul 9;285(5425):248-51
pubmed: 10398600
Blood. 2017 Jun 8;129(23):3100-3110
pubmed: 28416510
Annu Rev Immunol. 1994;12:991-1045
pubmed: 8011301
Mol Med. 2020 May 7;26(1):42
pubmed: 32380958
Horm Res Paediatr. 2020;93(2):73-75
pubmed: 32375153
Mediators Inflamm. 2010;2010:642462
pubmed: 20628562
Nat Immunol. 2013 Jul;14(7):741-8
pubmed: 23685786
J Biol Chem. 2012 Jun 29;287(27):22593-608
pubmed: 22549775
PLoS Pathog. 2017 Sep 7;13(9):e1006461
pubmed: 28880920
Eur J Clin Invest. 1999 May;29(5):413-25
pubmed: 10354198
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2232-42
pubmed: 26597304
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Sci Transl Med. 2020 Mar 18;12(535):
pubmed: 32188725
Cell Mol Immunol. 2020 Sep;17(9):992-994
pubmed: 32620787
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):296-301
pubmed: 14695889
Biochim Biophys Acta. 2000 Oct 18;1482(1-2):157-71
pubmed: 11058758
Nucleic Acids Res. 2004 Feb 10;32(3):989-96
pubmed: 14872058
Expert Rev Mol Med. 2008 Nov 04;10:e32
pubmed: 18980707
PLoS One. 2009 Jun 30;4(6):e6087
pubmed: 19564921
Food Nutr Bull. 2007 Sep;28(3 Suppl):S403-29
pubmed: 17988005
Glycobiology. 2004 May;14(5):431-41
pubmed: 14736726
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Opt Express. 2015 Oct 19;23(21):27724-38
pubmed: 26480435
BMC Mol Biol. 2008 Apr 01;9:32
pubmed: 18380906
Pharmacol Res. 2016 Sep;111:534-544
pubmed: 27378565
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
PLoS One. 2017 May 4;12(5):e0176069
pubmed: 28472045
Clin Exp Immunol. 2013 Aug;173(2):276-87
pubmed: 23607598
Proc Natl Acad Sci U S A. 2005 May 10;102(19):6843-8
pubmed: 15863613
J Crit Care. 2012 Jun;27(3):314.e1-11
pubmed: 21798705
Environ Res. 2015 Jul;140:10-7
pubmed: 25836720
Immune Netw. 2018 Aug 13;18(4):e27
pubmed: 30181915
JCI Insight. 2016;1(7):
pubmed: 27294203
Eur J Biochem. 1973 Sep 21;38(1):14-9
pubmed: 4774120
Antioxid Redox Signal. 2016 Apr 20;24(12):620-34
pubmed: 26715031
J Leukoc Biol. 2013 Jun;93(6):865-73
pubmed: 23446148
Nat Rev Immunol. 2008 Oct;8(10):776-87
pubmed: 18802444
Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):7783-7788
pubmed: 29997173
Cell Death Differ. 2018 Feb;25(2):392-405
pubmed: 29244050
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1333-41
pubmed: 21474825
J Biol Chem. 2002 Mar 1;277(9):7021-8
pubmed: 11748221
J Biol Chem. 2011 Dec 2;286(48):41736-41744
pubmed: 21990362
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Mol Biol (Mosk). 2004 Nov-Dec;38(6):1041-9
pubmed: 15612592
Nat Immunol. 2012 Sep;13(9):832-42
pubmed: 22842346
Mol Aspects Med. 2014 Dec;40:1-116
pubmed: 25010388
N Engl J Med. 2014 Dec 11;371(24):2309-19
pubmed: 25494270
Crit Care. 2014 Sep 09;18(5):503
pubmed: 25394679
Science. 2009 Mar 27;323(5922):1722-5
pubmed: 19264983
J Immunol. 2006 Sep 15;177(6):4037-46
pubmed: 16951367
Biochim Biophys Acta. 2016 Nov;1864(11):1620-9
pubmed: 27476953
Front Immunol. 2019 Aug 27;10:1967
pubmed: 31507595
Immunol Rev. 2017 Nov;280(1):74-82
pubmed: 29027228
Shock. 2006 Aug;26(2):174-9
pubmed: 16878026
Immunotargets Ther. 2015 May 26;4:101-9
pubmed: 27471716
Nature. 2002 Jul 11;418(6894):191-5
pubmed: 12110890
Cancer Res. 2011 May 1;71(9):3352-63
pubmed: 21505105
Cytokine Growth Factor Rev. 2018 Feb;39:92-101
pubmed: 29279185
J Biol Chem. 2011 Sep 9;286(36):31610-22
pubmed: 21757734
Blood. 2016 Nov 3;128(18):2218-2228
pubmed: 27683415
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11942-7
pubmed: 20547845
Eur Respir J. 2012 Jul;40(1):206-14
pubmed: 22267753
EMBO J. 2003 Oct 15;22(20):5551-60
pubmed: 14532127
Int J Infect Dis. 2014 Nov;28:111-6
pubmed: 25263503
Ann Transl Med. 2020 Feb;8(4):140
pubmed: 32175432
Tuberculosis (Edinb). 2008 May;88(3):203-11
pubmed: 18055265

Auteurs

Shoib S Siddiqui (SS)

Department of Medicine, University of California San Diego, La Jolla, CA 92093.
Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093.
Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA 92093.

Chirag Dhar (C)

Department of Medicine, University of California San Diego, La Jolla, CA 92093.
Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093.
Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA 92093.

Venkatasubramaniam Sundaramurthy (V)

Department of Medicine, University of California San Diego, La Jolla, CA 92093.
Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093.
Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA 92093.

Aniruddha Sasmal (A)

Department of Medicine, University of California San Diego, La Jolla, CA 92093.
Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093.
Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA 92093.

Hai Yu (H)

Department of Chemistry, University of California, Davis, CA 95616.

Esther Bandala-Sanchez (E)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.

Miaomiao Li (M)

Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo, NY 14214.

Xiaoxiao Zhang (X)

Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo, NY 14214.

Xi Chen (X)

Department of Chemistry, University of California, Davis, CA 95616.

Leonard C Harrison (LC)

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.

Ding Xu (D)

Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo, NY 14214.

Ajit Varki (A)

Department of Medicine, University of California San Diego, La Jolla, CA 92093; a1varki@ucsd.edu.
Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093.
Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA 92093.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH